Advancing Lymphodepletion-Free CAR-Ts to Transform Autoimmune Disease Treatment

• Examine how lymphodepletion impacts trial design, patient safety, and overall therapeutic outcomes in autoimmune indications
• Explore strategies to improve monitoring, immunogenicity assessment, and product development for lymphodepletion-free CAR-Ts
• Highlight emerging approaches to optimise persistence and efficacy without reliance on toxic preconditioning regimens

Speakers:

Maria Eugenia Alonso Ferrero

Director

Alexion Pharmaceuticals